U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

US stocks rose on Friday, May 2, as the S&P 500, Dow Jones Industrial Average, and the tech-heavy Nasdaq all posted ...

WisdomTree US High Dividend ETF (DHS) focuses on high-yield, quality U.S. equities, favoring defensive sectors. Read an ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Here are five cases of companies tied up in device and drug patent litigation since the beginning of 2025: 1. NuVasive infringed five patents from a spine surgeon, a jury determined in April. The jury ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.